Eagle Pharmaceuticals, Inc. Receivables, Fair Value Disclosure
Eagle Pharmaceuticals, Inc. had Receivables, Fair Value Disclosure of $4.65 million as of 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Notes › Fair Value Disclosures › Financial Instruments, Financial Assets, Balance Sheet Groupings
us-gaap:ReceivablesFairValueDisclosure · last filed 2023-03-23
- 2022-06-30: Receivables, Fair Value Disclosure $4.65M.
- 2022-03-31: Receivables, Fair Value Disclosure $4.54M.
- 2021-12-31: Receivables, Fair Value Disclosure $4.02M.
- 2021-09-30: Receivables, Fair Value Disclosure $3.79M.
| Period end | Receivables, Fair Value Disclosure |
|---|---|
| 2022-06-30 | $4.65M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $4.54M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $4.02M 10-K · filed 2023-03-23 |
| 2021-09-30 | $3.79M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $3.78M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $4.62M 10-Q · filed 2021-05-10 |